Novel vaccines that confer broad protection against influenza A viruses (IAV) are urgently needed. Hemagglutinin (HA) is the major influenza antigen targeted by protective immune responses. We have here developed a DNA vaccine that simultaneously presents HA from 18 subtypes of IAV to the immune system. The vaccine consists of a DNA plasmid mixture that encodes a variety of dimeric vaccine proteins. Each dimer expresses two different HA, as well as a targeting moiety directing the vaccine protein to antigen presenting cells (APC). When the vaccine proteins were targeted towards chemokine receptors 1, 3 and 5 (CCR1/3/5) on APC by means of MIP1α (CCL3), vaccinated mice were broadly protected against infection with H1N1, H3N2, H5N1 and H7N1 influenza viruses. Furthermore, antibody mediated protection against H1N1 was maintained when the H1 antigen was removed from the plasmid mixture, indicating that the diversity of HAs in the mixture promoted formation of antibodies specific for shared, conservative epitopes. The results may guide development of a broadly protective influenza A vaccine for humans.